DBV Technologies S.A.
DBVTNasdaq
$14.70
↓ -1.1%Jul 17 close · end-of-day
Price
1Y↑ +50.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$6.4B
Enterprise Value
$6.2B
P/E
—
P/S
1291.1
P/B
39.7
EV/EBITDA
—
PEG
—
FCF Yield
-2.7%
Dividend Yield
—
Revenue (TTM)
$4.9M
Net Income (TTM)
-$175.9M
Free Cash Flow (TTM)
-$170.6M
Gross Margin
—
Operating Margin
-3603.2%
Net Margin
—
ROE
—
ROIC
—
Debt / Equity
—
Net Cash
$174.9M
Return 1Y
+51.4%
Company profile
DBV Technologies S.A. engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus.
- CEO
- Daniel Tassé
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 80
- Website
- dbv-technologies.com
Management & directors
- Mohideen PharisChief Medical Officer
- Boucinha VirginieChief Financial Officer
- Trapp Kevin MichaelChief Commercial Officer
Roles derived from SEC Form 4 filings.
Earnings
DBVT Q2 2026 Earnings
Period ends 2026-06-30
MetricActualYoY
Revenue$700,000.00↓ -53.3%
Diluted EPS-$0.12↓ -61.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $11.3M | $5.7M | $4.8M | $15.7M | $4.2M | $5.6M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$158.8M | -$98.6M | -$96.6M | -$76.4M | -$116.6M | -$147.1M |
| Net income | -$159.6M | -$97.8M | $96.3M | $72.7M | -$113.9M | -$146.9M |
| Diluted EPS | — | -$1.78 | -$1.24 | -$0.76 | -$1.17 | -$1.05 |
| Operating cash flow | -$165.6M | -$108.2M | -$55.7M | -$79.7M | -$104.5M | -$121.2M |
| Free cash flow | -$168.4M | -$109.2M | -$56.4M | -$80.3M | -$106.8M | -$121.7M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -1408.7% | -1727.6% | -1994.9% | -486.0% | -2808.7% | -2609.2% |
| Net margin | -1415.0% | -1713.5% | 1987.5% | 462.3% | -2744.4% | -2607.3% |
| Line item | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $511,000.00 | $800,000.00 | $1.5M | $2.8M | $562,000.00 | $900,000.00 | $700,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$30.3M | -$23.9M | -$26.6M | -$41.1M | -$34.3M | -$45.1M | -$47.9M | -$50.6M |
| Net income | -$30.4M | -$23.0M | -$27.1M | -$41.9M | -$33.2M | -$44.8M | -$47.6M | -$50.4M |
| Diluted EPS | -$0.32 | -$0.23 | -$0.26 | -$0.31 | -$0.24 | -$0.24 | -$0.11 | -$0.12 |
| Operating cash flow | -$22.5M | -$12.3M | -$19.7M | -$33.9M | -$32.4M | -$35.2M | -$49.1M | -$52.6M |
| Free cash flow | -$22.9M | -$12.4M | -$19.7M | -$33.9M | -$32.6M | -$35.5M | -$49.5M | -$53.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -2829.1% | -4669.5% | -3325.0% | -2740.0% | -1235.7% | -8021.2% | -5322.2% | -7228.6% |
| Net margin | -2839.7% | -4503.9% | -3387.5% | -2793.3% | -1195.5% | -7968.5% | -5288.9% | -7200.0% |
Company news
Jul 17, 2026
Jul 16, 2026
- 4d agoDBV Technologies Q2 Earnings Call Highlightsmarketbeat.com
- 4d agoDBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Reportfinance.yahoo.com
- 4d agoDBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Updatefinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-01-29 | Mohideen Pharis· Chief Medical Officer | Sale | 534 | $4.86 | $2,595.24 | filing |
| 2025-12-18 | EPIC Bpifrance | Sale | 1,292,103 | $4.19 | $5.4M | filing |
| 2025-12-17 | EPIC Bpifrance | Sale | 2,036,990 | $4.84 | $9.9M | filing |
| 2025-12-17 | EPIC Bpifrance | Sale | 40,000 | $5.28 | $211,200.00 | filing |
| 2025-11-21 | Mohideen Pharis· Chief Medical Officer | Sale | 1,624 | $2.77 | $4,498.48 | filing |
| 2025-11-21 | Mohideen Pharis· Chief Medical Officer | Award | 44,000 | $0.00 | $0.00 | filing |
| 2025-11-21 | Boucinha Virginie· Chief Financial Officer | Award | 32,000 | $0.00 | $0.00 | filing |
| 2025-11-21 | Trapp Kevin Michael· Chief Commercial Officer | Award | 55,000 | $0.00 | $0.00 | filing |
| 2025-11-20 | Mohideen Pharis· Chief Medical Officer | Sale | 6,496 | $2.88 | $18,708.48 | filing |
| 2025-07-29 | Mohideen Pharis· Chief Medical Officer | Sale | 464 | $2.22 | $1,030.08 | filing |
Latest 10 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.